Another possibility could be the use of agents targeting mitochondrial ATP, which has also already showed promising results in melanoma cells with acquired resistance to BRAF inhibitors [63] and should be tested in melanoma cell lines with acquired resistance to MEK or cKIT inhibitors. The gene discussed is BRAF; the disease is melanoma.